AI brief of an SEC Form 8-K · Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Q2 revenue rises 55% to $243.6 million; raises 2026 ARCALYST guidance

Positive Impact 4 of 5 guidance Written later

Kiniksa reported second quarter 2026 total revenue of $243.6 million, up from $156.8 million a year earlier, and net income of $25.4 million, up from $17.8 million. The company raised its 2026 ARCALYST net product revenue guidance to $980 million to $995 million, from $930 million to $945 million, which signals higher expected sales for the main product.

Key points

  • Q2 2026 total revenue was $243.6 million, compared with $156.8 million in Q2 2025.
  • Q2 2026 net income was $25.4 million, or $0.30 per diluted share, compared with $17.8 million, or $0.23 per diluted share, in Q2 2025.
  • 2026 ARCALYST net product revenue guidance raised to $980 million to $995 million from $930 million to $945 million.
  • Cash, cash equivalents, and short-term investments were $525.9 million as of June 30, 2026, and the company had no debt.

The filing

CompanyKiniksa Pharmaceuticals International, plc (KNSA)
Form8-K, current report
Filed with the SECJul 28, 2026, 7:33 AM ET
Accession number0001730430-26-000031

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.